DK323587D0 - Protein - Google Patents

Protein

Info

Publication number
DK323587D0
DK323587D0 DK323587A DK323587A DK323587D0 DK 323587 D0 DK323587 D0 DK 323587D0 DK 323587 A DK323587 A DK 323587A DK 323587 A DK323587 A DK 323587A DK 323587 D0 DK323587 D0 DK 323587D0
Authority
DK
Denmark
Prior art keywords
proteolytically
viia
factor vii
sensible
stabilization
Prior art date
Application number
DK323587A
Other languages
Danish (da)
English (en)
Inventor
Soeren Erik Bjoern
Else Marie Nicolaisen
Finn Christoph Wiberg
Richard Woodbury
Original Assignee
Novo Industri As
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Industri As, Zymogenetics Inc filed Critical Novo Industri As
Priority to DK323587A priority Critical patent/DK323587D0/da
Publication of DK323587D0 publication Critical patent/DK323587D0/da
Priority to NO874548A priority patent/NO172235C/no
Priority to DE8888905735T priority patent/DE3871798T2/de
Priority to PCT/DK1988/000103 priority patent/WO1988010295A1/en
Priority to EP88905735A priority patent/EP0370036B1/de
Priority to JP63505496A priority patent/JPH03500963A/ja
Priority to AT88905735T priority patent/ATE76900T1/de
Priority to CA000570535A priority patent/CA1339815C/en
Priority to DK653989A priority patent/DK161097C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK323587A 1986-11-03 1987-06-25 Protein DK323587D0 (da)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK323587A DK323587D0 (da) 1987-06-25 1987-06-25 Protein
NO874548A NO172235C (no) 1986-11-03 1987-11-02 Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinforbindelser
DE8888905735T DE3871798T2 (de) 1987-06-25 1988-06-24 Modifizierter faktor vii/viia.
PCT/DK1988/000103 WO1988010295A1 (en) 1987-06-25 1988-06-24 MODIFIED FACTOR VII/VIIa
EP88905735A EP0370036B1 (de) 1987-06-25 1988-06-24 Modifizierter faktor vii/viia
JP63505496A JPH03500963A (ja) 1987-06-25 1988-06-24 変更７／７ａ因子
AT88905735T ATE76900T1 (de) 1987-06-25 1988-06-24 Modifizierter faktor vii/viia.
CA000570535A CA1339815C (en) 1987-06-25 1988-06-27 Modified factor vii/viia
DK653989A DK161097C (da) 1987-06-25 1989-12-21 Modificeret faktor vii/viia, dna-sekvens, som koder herfor, ekspressionsvektor indeholdende en saadan dna-sekvens, celle, der er transformeret med en saadan vektor og fremgangsmaade til fremstilling af modificeret faktor vii/viia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK323587A DK323587D0 (da) 1987-06-25 1987-06-25 Protein

Publications (1)

Publication Number Publication Date
DK323587D0 true DK323587D0 (da) 1987-06-25

Family

ID=8120606

Family Applications (2)

Application Number Title Priority Date Filing Date
DK323587A DK323587D0 (da) 1986-11-03 1987-06-25 Protein
DK653989A DK161097C (da) 1987-06-25 1989-12-21 Modificeret faktor vii/viia, dna-sekvens, som koder herfor, ekspressionsvektor indeholdende en saadan dna-sekvens, celle, der er transformeret med en saadan vektor og fremgangsmaade til fremstilling af modificeret faktor vii/viia

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK653989A DK161097C (da) 1987-06-25 1989-12-21 Modificeret faktor vii/viia, dna-sekvens, som koder herfor, ekspressionsvektor indeholdende en saadan dna-sekvens, celle, der er transformeret med en saadan vektor og fremgangsmaade til fremstilling af modificeret faktor vii/viia

Country Status (7)

Country Link
EP (1) EP0370036B1 (de)
JP (1) JPH03500963A (de)
AT (1) ATE76900T1 (de)
CA (1) CA1339815C (de)
DE (1) DE3871798T2 (de)
DK (2) DK323587D0 (de)
WO (1) WO1988010295A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DE69032029T2 (de) * 1989-12-29 1998-08-20 Zymogenetics, Inc., Seattle, Wash. Hybrides protein c
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7176288B2 (en) 2000-09-13 2007-02-13 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
AU2001287550B2 (en) * 2000-09-13 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor VII variants
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
BR0208203A (pt) * 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003027147A2 (en) * 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP1451315B1 (de) * 2001-11-02 2014-05-21 Novo Nordisk Health Care AG Menschliche gerinnungsfaktor-vii-polypeptide
DK1499719T3 (da) 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CA2502162C (en) 2002-09-30 2014-04-15 Maxygen Holdings Ltd. Fvii or fviia variants having increased clotting activity
ES2386010T3 (es) 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
SI1644504T1 (sl) 2003-06-19 2010-06-30 Bayer Healthcare Llc Variante Gla domene faktorja VII ali VIIa
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
RU2396347C2 (ru) 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
WO2008127702A2 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
FR2917414B1 (fr) * 2007-06-15 2012-07-13 Lab Francais Du Fractionnement Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
RU2589254C2 (ru) 2009-06-09 2016-07-10 ПРОЛОНГ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Композиции гемоглобина
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461040A1 (fr) * 1979-07-09 1981-01-30 Inst Textile De France Procede et dispositif pour l'obtention d'un fil presentant sur sa longueur des zones de torsion alternativement de sens inverse
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
EP0201153A3 (de) * 1985-02-09 1987-10-07 Beecham Group Plc Modifiziertes Enzym und Verfahren zu dessen Herstellung
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym

Also Published As

Publication number Publication date
CA1339815C (en) 1998-04-14
ATE76900T1 (de) 1992-06-15
DK653989A (da) 1989-12-21
DK161097B (da) 1991-05-27
DE3871798T2 (de) 1993-05-13
EP0370036A1 (de) 1990-05-30
DK653989D0 (da) 1989-12-21
EP0370036B1 (de) 1992-06-03
JPH03500963A (ja) 1991-03-07
DK161097C (da) 1991-11-11
DE3871798D1 (de) 1992-07-09
WO1988010295A1 (en) 1988-12-29

Similar Documents

Publication Publication Date Title
DK323587D0 (da) Protein
DK105489D0 (da) Polypeptid
KR880701105A (ko) 신규 응혈촉진 단백질
DE69129865D1 (de) Osteogene peptide
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
DE68927088D1 (de) Menschlicher Gefässpermeabilitätsfaktor
LU90458I2 (fr) Refacto
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
ES8802235A1 (es) Procedimiento para preparar un polipeptido
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
KR900700469A (ko) 우레탄-보호된 아미노산-n-카르복시무수물
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
DE3873397D1 (de) Bifunktionelle proteine.
EP0423224A4 (en) Leader sequence inducing a post-translational modification of polypeptides in bacteria, and gene therefor
ATE144535T1 (de) Plättchen blockierende peptide
DE59810198D1 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
MX9203879A (es) Muteina de il-6 con cisteina parcialmente suprimida.
DK39591A (da) Peptidforbindelser
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
DK262986A (da) Peptidmateriale med thymushumoral aktivitet
FR2569111B1 (fr) Nouveaux medicaments contenant des tripeptides
FI942392A (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
DK0563385T3 (da) Thrombolytisk peptid, fremstilling deraf og thrombolytisk middel
AU637589B2 (en) Ancrod proteins, their production and use

Legal Events

Date Code Title Description
ATS Application withdrawn